ChondroCelect® available and reimbursed in Belgium
Leuven -TiGenix is pleased to announce that ChondroCelect®, its cell based medicinal product for cartilage repair in the knee, will be available and reimbursed for hospital use in Belgium with effect from May 1st 2011.
ActoGeniX, a Dutch drug company whose lead candidate is focused on inflammatory bowel disease, has raised €13.5 million in second-round funding.